Display options
Cite
Rhame FS. When to start antiretroviral therapy. Curr Infect Dis Rep. 2011;13(1):60-7doi: 10.1007/s11908-010-0154-8.
Rhame, F. S. (2011). When to start antiretroviral therapy. Current infectious disease reports, 13(1), 60-7. https://doi.org/10.1007/s11908-010-0154-8
Rhame, Frank S. "When to start antiretroviral therapy." Current infectious disease reports vol. 13,1 (2011): 60-7. doi: https://doi.org/10.1007/s11908-010-0154-8
Rhame FS. When to start antiretroviral therapy. Curr Infect Dis Rep. 2011 Feb;13(1):60-7. doi: 10.1007/s11908-010-0154-8. PMID: 21308456.
Copy Download .nbib Format: NLM
Share it on

Curr Infect Dis Rep. 2011 Feb;13(1):60-7. doi: 10.1007/s11908-010-0154-8.

When to start antiretroviral therapy.

Current infectious disease reports

Frank S Rhame

Affiliations

  1. Abbott Northwestern Hospital, Clinic 42, Mailstop 17200, 2545 Chicago Avenue South, Minneapolis, MN, 55404, USA, [email protected].

PMID: 21308456 DOI: 10.1007/s11908-010-0154-8

Abstract

Antiretrovirals perform superbly in combating HIV infection. But when to initiate therapy in asymptomatic, nonpregnant, hepatitis-free, HIV-infected persons is not securely established. Of two completed randomized trials using modern therapy, a Haitian trial demonstrated a benefit to initiating therapy between 200 and 350 CD4 cells/mm(3) as compared with less than 200 CD4 cells/mm(3) and an international trial demonstrated a benefit to starting at greater than 350 CD4 cells/mm(3) as compared with less than 250 CD4 cells/mm(3). Many observational cohorts support initiating treatment at less than 350 CD4 cells/mm(3). Of these, three large studies supported initiation at less than 350 cells/mm(3), less than 450 CD4 cells/mm(3), and less than 500 CD4 cells/mm(3), respectively, but only the last supported starting at higher counts. Such studies are not probative, given the problem of confounding. No conventional antiretroviral regimen is free of long-term adverse effects, especially over decades of use. All are expensive and require expensive monitoring. When resources are restricted, initiation of antiretrovirals for persons with high CD4 count diverts treatment from more needy persons. Pathophysiological considerations favor universal treatment because antiretrovirals mitigate systemic inflammation, which aggravates atherosclerosis. There are suggestions that HIV hastens the natural decline of cognitive, renal, and pulmonary function as well as bone mineral loss; the mechanism(s) are uncertain, as is the ability of antiretrovirals to counteract the probable acceleration. The four major guideline panels, although all have issued updates in the past year, are not consistent in recommendations for treatment of HIV-infected persons with counts greater than 350 CD4 cells/mm(3).

References

  1. J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):25-31 - PubMed
  2. Environ Mol Mutagen. 2007 Apr-May;48(3-4):166-72 - PubMed
  3. Front Biosci. 2004 Jan 01;9:338-41 - PubMed
  4. N Engl J Med. 1992 Feb 13;326(7):437-43 - PubMed
  5. Maturitas. 1990 Sep;12(3):259-85 - PubMed
  6. Ann Intern Med. 1992 Dec 15;117(12):1016-37 - PubMed
  7. Rheumatology (Oxford). 2008 Jan;47(1):3-7 - PubMed
  8. Circulation. 1981 Jul;64(1):42-6 - PubMed
  9. N Engl J Med. 1999 Jun 10;340(23):1801-11 - PubMed
  10. N Engl J Med. 2010 Jul 15;363(3):257-65 - PubMed
  11. Lancet. 2010 Jul 31;376(9738):340-5 - PubMed
  12. Am J Epidemiol. 2008 Feb 15;167(4):492-9 - PubMed
  13. PLoS Med. 2008 Oct 21;5(10):e203 - PubMed
  14. N Engl J Med. 2009 Apr 30;360(18):1815-26 - PubMed
  15. BMJ. 2008 Apr 26;336(7650):924-6 - PubMed
  16. J Acquir Immune Defic Syndr. 2004 May 1;36(1):645-7 - PubMed
  17. J Infect Dis. 2008 Apr 15;197(8):1133-44 - PubMed
  18. AIDS. 1998 Jul 30;12(11):1259-65 - PubMed
  19. N Engl J Med. 1990 Apr 5;322(14):941-9 - PubMed
  20. JAMA. 2002 Jul 17;288(3):321-33 - PubMed
  21. Atherosclerosis. 2006 Mar;185(1):1-11 - PubMed
  22. J Am Coll Cardiol. 2008 Aug 12;52(7):569-76 - PubMed
  23. AIDS. 2009 May 15;23(8):929-39 - PubMed
  24. Lancet. 1994 Apr 9;343(8902):871-81 - PubMed
  25. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 1;11(2):142-50 - PubMed
  26. N Engl J Med. 2010 Oct 14;363(16):1495-7 - PubMed
  27. Scand J Infect Dis. 2009;41(11-12):808-17 - PubMed
  28. JAMA. 2010 Jul 21;304(3):321-33 - PubMed
  29. HIV Med. 2009 May;10(5):318-27 - PubMed
  30. Antivir Ther. 2008;13(2):177-87 - PubMed
  31. Lancet. 2009 Apr 18;373(9672):1352-63 - PubMed
  32. Prev Med. 1991 Jan;20(1):47-63 - PubMed
  33. N Engl J Med. 2009 Aug 20;361(8):822-3; author reply 823-4 - PubMed
  34. JAMA. 1994 Aug 10;272(6):437-42 - PubMed
  35. J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):246-8 - PubMed
  36. Arteriosclerosis. 1990 Nov-Dec;10(6):1051-7 - PubMed

Publication Types